GSK3B and early-onset autosomal dominant Alzheimer disease: The diseases of GSK-3β activated by LPS are oral cancer (Lee et al., 2017), esophageal cancer (Liu et al., 2023) and Alzheimer’s disease (Jiang et al., 2021).